The partnership will focus on developing the small molecule inhibitors as therapeutics to treat cancer in humans.
TPP CEO Tom Brown said the agreement will allow the company to work with Sprint Bioscience, and look forward to utilising their expertise in fragment-based drug discovery and development.
"Choline Kinase is an exciting metabolic target and fits well within the rest of TPP’s cancer metabolism portfolio," Brown added.
The cancer cells require increased choline kinase activity to generate the cell membrane phospholipid component phosphatidylcholine and enzyme’s activity is involved in cell transformation.
Sprint is running a fragment-based drug discovery program to identify small molecules that target choline kinase a.